What Anakinra Does
Anakinra is a recombinant interleukin-1 (IL-1) receptor antagonist that blocks both IL-1α and IL-1β from binding to the IL-1 type 1 receptor, thereby preventing the inflammatory cascade that drives multiple autoinflammatory and inflammatory diseases. 1
Mechanism of Action
Anakinra is a 153-amino acid protein that differs from native human IL-1 receptor antagonist by a single methionine residue at its amino terminus 1. It competitively inhibits IL-1 binding to IL-1R1, preventing the downstream production of secondary inflammatory mediators including:
- Prostaglandins
- Cytokines
- Chemokines 2
This blockade effectively quenches IL-1-mediated inflammation and prevents tissue damage and organ dysfunction 2.
FDA-Approved Clinical Uses
Anakinra is FDA-approved for:
Neonatal-Onset Multisystem Inflammatory Disease (NOMID/CINCA) - Dosed at 1-8 mg/kg/day subcutaneously 3, 1
Deficiency of Interleukin-1 Receptor Antagonist (DIRA) - Dosed at 1-8 mg/kg/day subcutaneously 3, 1
Rheumatoid Arthritis - Standard adult dose of 100 mg subcutaneously daily 1, 4
Guideline-Supported Uses
Beyond FDA indications, major rheumatology guidelines support anakinra for:
- Cryopyrin-Associated Periodic Syndromes (CAPS) including Muckle-Wells syndrome at 1-8 mg/kg/day 3
- Systemic Juvenile Idiopathic Arthritis (sJIA) as initial monotherapy, particularly effective for controlling systemic features and allowing glucocorticoid reduction 5
- Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency (MKD) as alternative IL-1 inhibitor 3
Pharmacokinetics and Administration
- Administered as daily subcutaneous injection 1
- Short duration of action allows for rapid on/off effects 2
- Clinical benefits typically evident within days of initiation 2
- Can be used continuously for years (documented use >12 years) 2
Safety Profile
Anakinra has an exceptionally favorable safety profile compared to other biologics, with notably rare opportunistic infections including tuberculosis reactivation, even in at-risk populations 2. Common adverse effects include:
- Injection site reactions (most common)
- Rare: neutropenia, infections, drug reactions with eosinophilia and systemic symptoms 1
Critical Drug Interaction
Do not combine anakinra with TNF-blocking agents - this combination significantly increases serious infection risk and neutropenia rates 1.
Emerging and Off-Label Uses
Research supports anakinra's effectiveness in:
- Recurrent pericarditis (third-line therapy per European Society of Cardiology 2015 guidelines) 6, 7
- Acute calcium pyrophosphate deposition disease (CPPD) flares with 76% positive response rate 8
- ST-segment elevation myocardial infarction (STEMI) to reduce inflammatory response and heart failure risk 9
- Drug-resistant epilepsy including FIRES syndrome 10
Practical Considerations
- The prefilled syringe formulation does not allow doses <20 mg to be administered 1
- Can be used as a diagnostic tool for undefined IL-1-mediated diseases due to rapid onset and excellent safety profile 2
- For systemic JIA, some experts prefer starting with anakinra (short-acting) over longer-acting IL-1 inhibitors to allow flexibility in dose adjustment 5
- Treat-to-target strategies using clinical symptoms and inflammatory markers (CRP <5-10 mg/L) guide optimal dosing 3